Drug Profile


Alternative Names: LU 57291; PEG-hirudin - Speedel; SPP-200

Latest Information Update: 29 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antithrombotics; Hirudins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders; Coronary disorders; Unstable angina pectoris; Vascular graft occlusion

Most Recent Events

  • 22 Dec 2009 No development reported - Phase-II for Vascular graft occlusion in USA (Parenteral)
  • 29 Aug 2006 Speedel has retained all development, commercialisation and marketing rights to pegmusirudin from Abbott Laboratories
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top